EIF6 and leukemia: Our results support EIF6 as a potential therapeutic target in SDS patients, since pharmacologic inactivation of EIF6 could mimic genetic inactivation of EIF6, thereby reducing leukemia risk and improving hematopoietic function in SDS patients.